The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy

Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack

(2015) Ercan Cacan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

FDA Approves New Agent for Multiple Myeloma

(2015) M. P. Fenichel   JNCI-Journal of the National Cancer Institute

MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF B Activation in Breast Cancer

(2015) S. Munoz-Galvan et al.   MOLECULAR CANCER THERAPEUTICS

Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function

(2015) Yamei Hu et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A

(2015) Pui-Mun Wong et al.   Nature Communications

FDA Approves New Agent for Multiple Myeloma

(2015) M. P. Fenichel   JNCI-Journal of the National Cancer Institute

Hedgehog Inhibitors in Rhabdomyosarcoma: A Comparison of Four Compounds and Responsiveness of Four Cell Lines

(2015) Rosalie Ridzewski et al.   Frontiers in Oncology

Quantitative regulation of vesicle formation in yeast non-specific autophagy

(2014) Jiefei Geng et al.   Autophagy

Outcome of advanced, unresectable conventional central chondrosarcoma

(2014) Annemiek M. van Maldegem et al.   CANCER

Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation

(2014) C Kao et al.   Cell Death & Disease

Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma

(2013) Andrew Poklepovic et al.   INVESTIGATIONAL NEW DRUGS

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

(2013) X Sui et al.   Cell Death & Disease

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

(2012) Bilal Piperdi et al.   Journal of Thoracic Oncology

New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy

(2012) J S Long et al.   ONCOGENE

Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer

(2011) Benjamin Besse et al.   LUNG CANCER

Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer

(2010) Kevin Dalby et al.   Autophagy

Fas/FasL expression in colorectal cancer. An immunohistochemical study.

(2010) Anna Pryczynicz et al.   FOLIA HISTOCHEMICA ET CYTOBIOLOGICA

Regulation of Autophagy Through Multiple Independent Hypoxic Signaling Pathways

(2009) Kasper Rouschop et al.   CURRENT MOLECULAR MEDICINE

Chondrosarcoma in the United States (1973 to 2003): An Analysis of 2890 Cases from the SEER Database

(2009) Angela Ylenia Giuffrida et al.   JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib

(2009) T. A. Luster et al.   MOLECULAR CANCER THERAPEUTICS

Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization

(2008) M. A. Qadir et al.   BREAST CANCER RESEARCH AND TREATMENT

Blocked Autophagy Sensitizes Resistant Carcinoma Cells to Radiation Therapy

(2008) A. Apel et al.   CANCER RESEARCH

Heat shock proteins: essential proteins for apoptosis regulation

(2008) D. Lanneau et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE